News

Ficlatuzumab is a humanized IgG1 antibody that binds to the hepatocyte growth factor (HGF) ligand with high affinity and specificity to inhibit the biological activities of the HGF/c-Met

Janssen said the drug is used to treat patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent symptomatic venous thromboembolism (VTE). The company

Financial details for the research partnership have not been disclosed. As part of the research partnership, both companies will focus on screening for biased ligands against an undisclosed

The mobile cloud-based solution will eliminate servers, forgo the need of internal staff constantly upgrading software and improving the customers’ experience. Using MaaS360’s secure document sharing feature, the

Lorus has discovered IL-17E (also known as IL-25) cytokine that plays a vital role in inflammation and has potent anticancer properties. Lorus president and CEO Aiping Young said

The Study 116, a randomized, double-blind study, will enroll 160 patients to evaluate the utility of GS-1101 in combination with various chemoimmunotherapies in previously treated CLL patients. The

The two patents, owned by Aptalis and licensed to Cephalon, will expire in 2023 and 2025. Aptalis president John Fraher said, "Aptalis Pharmaceutical Technologies endeavors to offer to

The UPS 4 blister line provides primary packaging into a series of materials including PVC, PVC/PVDC, Aclar and Alu/Alu, by processing solid oral dose products. Almac manufacturing operations

The patent covers Inovio’s synthetic consensus HPV antigens, DNA constructs and vaccines that include these antigens, including VGX-3100, cervical dysplasia/cancer vaccine. The methods used for treating patients with